Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of rilvegostomig (AZD5863) in CLDN18.2-positive advanced or metastatic solid tumors
NL-OMON59860Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of rilvegostomig in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC) and 1 more (4 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of adverse events, adverse events of special interest, dose-limiting toxicities, and serious adverse events, Adverse events leading to discontinuation of rilvegostomig and 2 more. Started Sep 2024; status: recruiting.
02
Drugs
rilvegostomig
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON59860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59860.